New immune cell therapy tested for tough blood cancers

NCT ID NCT07447726

Summary

This early-stage study is testing a new type of CAR-T cell therapy for adults with large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see if it helps shrink tumors. Only three participants will be enrolled to receive a single infusion of the modified immune cells and be closely monitored.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.